Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsSyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteChromosomes, Human, Pair 5Leukemia, MyeloidAnemia, SideroblasticAzacitidineBone MarrowThalidomideChromosome AberrationsKaryotypingMonosomyPreleukemiaMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesTreatment OutcomeAnemia, AplasticPancytopeniaChromosomes, Human, Pair 7Cytogenetic AnalysisPrognosisLeukemiaAcute DiseaseBone Marrow CellsChromosome DeletionGranulocyte Precursor CellsHematopoietic Stem Cell TransplantationBone Marrow DiseasesNeoplasms, Second PrimaryAntimetabolites, AntineoplasticTrisomyIron OverloadCytogeneticsErythrocyte TransfusionRemission InductionCytarabineSurvival AnalysisTransplantation, HomologousHematologic AgentsHematopoietic Stem CellsAntineoplastic AgentsChelation TherapyAntigens, CD34ThrombocytopeniaBlood TransfusionVidarabineErythropoietinTransplantation ConditioningRecurrenceSurvival RateDown SyndromeBlast CrisisMetabolic Syndrome XBone Marrow ExaminationMutationDisease ProgressionHematopoiesisRetrospective StudiesBlood Cell CountHematologic DiseasesGranulocyte Colony-Stimulating FactorIn Situ Hybridization, FluorescenceAntineoplastic Combined Chemotherapy ProtocolsSweet SyndromeAnemia, MacrocyticAnemiaChromosomes, Human, Pair 8Refractory Period, ElectrophysiologicalCore Binding Factor Alpha 2 SubunitKaryotypeChromosome DisordersHematologic NeoplasmsErythroid Precursor CellsHaploinsufficiencyTranslocation, GeneticBone Marrow TransplantationPrimary MyelofibrosisArabinonucleosidesFlow CytometryChromosomes, Human, Pair 20Drug Administration ScheduleLeukemia, Myelomonocytic, AcuteFatal OutcomeIron Chelating AgentsDisease-Free SurvivalHematinicsRisk FactorsBusulfanErythroid CellsImmunophenotypingAntilymphocyte SerumDNA Modification MethylasesFollow-Up StudiesHemoglobinuria, ParoxysmalErythroblastsIdarubicinThrombocytosis